Mobilization of circulating haemopoietic cells (blood stem cells) by GM-CSF in patients with malignancies.
Autologous reinfusion of circulating haemopoietic progenitor and stem cells (blood stem cell transplantation) has emerged as an alternative to autologous bone marrow transplantation in a variety of malignant diseases. Major obstacles associated with harvest of blood stem cells by leukapheresis are: 1. relatively high costs, and 2. discomfort caused to the patient, as generally five to ten settings of leukapheresis are necessary to harvest a number of blood stem cells sufficient for haemopoietic restitution following myeloablative therapy. GM-CSF recently has been shown to effectively increase circulating haemopoietic cells, when given subsequent to even highly-toxic therapy. This report summarizes our data on mobilization of blood stem cells by GM-CSF cells in multiple myeloma patients.
Universitätsklinikum Rudolf Virchow, Charlottenburg, Abteilung Innere Medizin, Germany.
S
S
Serke
A
A
Kirsch
D
D
Huhn
D003131:Combined Modality Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007937:Leukapheresis; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor